$ALMS

On September 9, 2026, significant insider trading activity was reported. Alumis Inc. (ALMS) director acquired $10.7M in shares, while NVIDIA (NVDA) director sold $235.6M. Greenwave (GWAV) CEO bought $8M in shares, and BELITE BIO (BLTE) executives sold $31.9M. Workday (WDAY) director sold $17.9M in shares. Dell (DELL) insiders sold $48.1M. Inhibrx (INBX) and Cytosorbents (CTSO) directors also made notable purchases.

Alumis (ALMS) stock rose 6.3% in pre-market trading after presenting long-term skin-clearance data for envudeucitinib at the Cantor Fitzgerald Global Healthcare Conference. Management highlighted potential partnerships and insider Srinivas Akkaraju bought 986,000 shares. The FDA application for envudeucitinib is expected in Q4 2026.

AKKARAJU SRINIVAS sold 96,131 indirectly-held shares of ALUMIS INC. (ALMS) at $10.55 ($1.01M total) across 2 trades on 2026-09-08.

AKKARAJU SRINIVAS purchased 986,721 indirectly-held shares of ALUMIS INC. (ALMS) at an average of $10.87 ($10.63–$11.17, $10.73M total) across 4 trades over 2026-09-04 to 2026-09-08.

Alumis Inc. (ALMS) reported that its Phase 2b LUMUS trial of envudeucitinib in systemic lupus erythematosus did not meet primary or secondary endpoints in the overall population. However, a prespecified subgroup with high interferon gene signature showed numerically higher responses. The company plans to discuss Phase 3 trial design with regulators. Envudeucitinib was generally well tolerated.

Alumis Inc. (ALMS) shares dropped 57% after its Phase 2b lupus study missed primary goals, though a patient subgroup showed promising results. The company plans to discuss a late-stage trial with regulators. Wells Fargo and Baird lowered price targets but maintained positive ratings. ALMS is down 3% year-to-date.

Alumis (ALMS) reported its Phase IIb LUMUS trial for envudeucitinib in lupus failed to meet primary and secondary endpoints, causing shares to drop 50%. The trial involved 408 patients and measured disease activity improvement over 48 weeks.

Alumis stock fell 54.2% in pre-market trading after its Phase 2b LUMUS trial for envudeucitinib in systemic lupus erythematosus missed primary and secondary endpoints. A subgroup of patients showed positive responses, but the overall trial population was under-represented. The company plans to discuss a Phase 3 program with regulators. The Nasdaq, S&P 500, and Dow Jones also declined, exacerbating the sell-off.

Alumis Inc. (ALMS) reported that its Phase 2b LUMUS trial of envudeucitinib for systemic lupus erythematosus (SLE) did not meet primary and secondary endpoints in the overall population. However, a prespecified subgroup of patients with high interferon gene signature (IFNGS-high) showed robust responses. The company plans to discuss Phase 3 development with regulators. Envudeucitinib was well tolerated. Alumis remains on track to submit an NDA for envudeucitinib in moderate-to-severe plaque psor

James B. Tananbaum, via funds managed by Foresite Capital, disclosed a 14.5% stake in Latigo Biotherapeutics, Inc. in a Schedule 13D filed Aug. 17, 2026, after the company’s Aug. 10, 2026 IPO. The filing says there are no current plans for major transactions or board changes, though shares may be bought or sold.